Viral Inactivation: Ensuring Safety in Biopharmaceuticals

Introduction: Why Viral Inactivation is So Important?

Do you ever wish to know the processes that are taken by vaccines, life saving therapeutics to become safe enough to inject into our bodies? One of them is viral inactivation, through which one makes certain that no viruses are present in the biopharmaceutical products. Despite the fact that it may sound like a complicated string of words, it is a process that is crucial in coming up with vaccines, plasma-derived products, and recombinant proteins.

Many drugs of the 21st-century production stem from mammalian cells, bacteria, or yeasts, thus making cell culture paramount to pharmaceutical businesses. Thus it should be noted that such cells can contain viruses. If not containing such contamination they may lead to serious infections. That is where viral inactivation comes in as it is a science that ‘walls off’ patients from viral diseases.

This article discusses the meaning of this process, kinds of it, methods of it, and on what basis it is a significant foundation of drug safety.

What Is Viral Inactivation?

It can be described as the process of rendering viral particles in a biological product non-infective while still physically present in the product. Filtration and separation are different from inactivation because the latter involves rendering the viruses inactive and unable to replicate or harm.

This is different from the disinfection or sterilization process. While other methods will require the elimination of all forms of life, viral inactivation only deactivates viruses, thus retaining the quality of the product, for example plasma or monoclonal antibodies.

Where Is Viral Inactivation Used?

It is used rigorously in:

• Such plasma derived products as clotting factors
• Monoclonal antibody production
• Recombinant protein therapeutics
• Vaccine development
• Cell therapy and gene therapy workflows

Different areas have their risk and regulatory control measures, but the objective is unchanged across the globe: eradicate the virus and protect the product.

How Does Viral Inactivation Work?

There is no one-size-fits-all method. The strategy depends on:

• The fact of the virus’s envelopment or lack of it
• The nature of the biopharmaceutical product
• The acceptable exposure time
• Thermal and pH stability of the final product

The inactivation agents disrupt the viral structure through damaging it in a way that it cannot attack the host cells by interfering with its envelope, proteins or nucleic acid (RNA or DNA).

Types of Viruses Targeted

Knowledge of different viruses helps to comprehend the difficulties of inactivating them.

1. Enveloped Viruses

These viruses have an outer lipid layer and are less resistant and relatively easy to inactivate. Examples:

• HIV
• Hepatitis B and C
• Influenza

2. Non-Enveloped Viruses

Some lack the lipid layer and as such it is even harder to work with them. Examples:

• Parvovirus
• Hepatitis A
• Norovirus

As a result of this structural difference, the multiple inactivation strategies are employed in a single bioprocess.

Viral Inactivation Techniques in Biopharma

1. Solvent/Detergent (S/D) Treatment

This is the most widely used technique for inactivating enveloped viruses; it is also the most frequently employed procedure of five methods for inactivating viruses. How it works is that it inhibits the viral lipid envelope with the following:

• Solvent: Tri-n-butyl phosphate (TNBP)
• Detergents: Triton X-100 or Polysorbate 80

Advantages:

• Rapid
• Highly effective against enveloped viruses
• Minimal product degradation

Limitations:

• Not effective against non-enveloped viruses

2. Low pH Treatment

The protein solution is maintained at an acidic pH of 3.5-4.0 for a few hours depending on the size of the protein sample.

• Used in: IgG antibody purification

Pros:

• Good for enveloped viruses
• No harsh chemicals required

Cons:

• Depends on the proteins that are resistant to low pH.

3. Heat Treatment (Pasteurization)

It will be heated at 60°C for 10 hrs under the stabilizing step.

• Application: Plasma products

This is not boiling, it is simmering to keep the proteins intact; they need to be heated gently so as not to lose their shape and texture.

4. UV-C Irradiation

UV radiation mutagenic to viruses thus affects its nucleic acids. Often used in:

• Blood products
• Vaccine production

Benefit: No chemicals needed

Limitation: Limited penetration, so not great for opaque or dense solutions.

5. Caprylic Acid Precipitation

It is applied in the plasma fractionation particularly when preparing albumin. This eliminates viruses and causes sedimentation of solids which are impurities in the solution.

6. Gamma Irradiation

Penetrative ionizing radiation is effective against both types of viruses. They are mostly applicable in the sterilization of final containers and equipment.

Inactivation vs Removal: A Two-Pronged Approach

A lot of processes in manufacturing destroy the virus through both inactivation and removal. For example:

• Disinfection negates the capabilities of such viruses through the use of chemicals and heat.
• Removal, on the other hand, employs filters or chromatography to mechanically remove the viruses present in the product.

The two are an effective mix in a viral clearance approach.

How Is It Validated?

It is important to note that regulatory agencies such as the FDA or EMA demand viral clearance validation studies. These involve:

• On spiking the product with model viruses
• Running the full process
• It is much more challenging as the number of logs reduced normally ranges between 4 – 6 is expected.

All these studies are useful to show that the viral inactivation process is consistent and reproducible.

Real-World Example: Recombinant Protein Production

Suppose you have been tasked with generating a monoclonal antibody from the CHO (Chinese Hamster Ovary) cells. It is for this reason that there is always theoretical possibility of viral contamination from:

• Raw materials (like serum or enzymes)
• Cell line instability
• Cross-contamination in the facility

Some of the strategies that would be considered as traditional viral clearance strategies are:

• Low pH inactivation
• Protein A chromatography (removal)
• Nanofiltration (removal)
• Virus spike testing and validation

Each one of them is aimed at either inactivating or eliminating viral hazards.

Is it not possible to block all the viruses?

It’s a fair question. Nonetheless, despite the fact that the nanofiltration can filter a particle with a size of not more than 20 nm, non-enveloped viruses can still pass through. On the plus side, a filter can clog, degrade or fail. They are thus areas that inactivation is helpful because they address what filtration may not identify.

Also, some processes cannot be filtered such as processes involving viscous solutions or solutions where the contents are opaque. Consequently, it is more appropriate to use a chemical or thermal inactivation process.

Impact on Vaccine Development

With reference to the killed vaccines, the inactivation process forms part of the vaccine product.

Examples include:

• Inactivated polio vaccine (IPV)
• Rabies vaccine
• Hepatitis A vaccine

Here, inactivation has to retain antigenicity and totally eliminate any risk of an infective virus surviving the preparation process.

Challenges in Viral Inactivation

Despite that, manufacturers face various challenges when using the tools:

1. Product Stability

Some proteins cannot survive in heat or dilute hydrochloric acid. Inactivation must be done in such a way that the protein’s structure is not affected.

2. Viral Resistance

Non-encapsulated viruses such as Parvovirus B19 are very stable and difficult to combat, which could harm the product.

3. Scalability

There are challenges of scaling down laboratory established procedures to that of an industry.

4. Regulatory Pressure

Every step must be approved, recorded and re-approved in case of any change in the process involved.

Future Directions and Innovations

It has also been noted that the recent methods of virus inactivation are not the same anymore.

• Photochemical Inactivation: Involves the use of light and photosensitizer/methylene blue to eliminate nucleic acids
• Next-Gen Detergents: Less toxic, more eco-friendly chemicals
• AI-Driven Modeling: Predicting virus clearance efficiency before physical testing

These are aimed at increasing efficiency, effectiveness, and compliance of processes.

Conclusion

Actually, viral inactivation is more than simply the idea of ​​increased security, but the fundamental concept of the production of pharmaceuticals. It has guarded the lives of millions of people through vaccines, such as those against flu and COVID-19, and even through monoclonal antibodies. While the process occurs out of sight, it plays the role of checking what you put into your systems is not dangerous in ways that are not immediately apparent.

Thus, the biopharmaceutical industry knows what is at stake for its products and is dedicated to enhancing viral inactivation techniques so it does not become a victim of invisible foes that may compromise our advanced therapies.

Are you in search of the latest methods of virus elimination in the treatment of bioprocessing equipment? To learn more about high-performance solutions to address modern GMP needs of the industries, please visit BaiLun Bio.